Public Health On Call

687 - Two New RSV Products to Protect Infants

11.13.2023 - By Johns Hopkins Bloomberg School of Public HealthPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

RSV—respiratory syncytial virus—is a common infection that causes cold-like symptoms but can become very severe in young children and is the leading cause of hospitalization for babies under 1. Dr. Ruth Karron, director of the Johns Hopkins Vaccine Initiative, talks with Dr. Josh Sharfstein about two new products, a vaccine for pregnant people and an antibody treatment for babies, that could substantially lower the rates of severe infections among children. However, the rollout has been slow and people may still have a hard time getting them for their children as RSV season kicks into gear.

More episodes from Public Health On Call